DIRS.INFO The most relevant business & tech news

☆ India wants to be a developed nation by 2047. Here are 4 critical areas Modi can't ignore
▼ + stars: | 2024-06-20 | by ( Charmaine Jacob | In Charmainemariajacob | ) www.cnbc.com time to read: +7 min

India has undergone a massive infrastructure push and has made significant strides in connecting and modernizing its highways, railways and airports. He's going to double down on that," said Samir Kapadia, CEO of India Index and managing principal at Vogel Group. "Along with creating physical infrastructure, India needs to remain steadfast on the structural reforms ... Increase foreign investmentsFrom veteran emerging markets investor Mark Mobius to global strategist David Roche, market experts remain bullish on India. Foreign direct investments into the country needs to however pick up pace to further drive economic growth and development, analysts told CNBC.

Persons: Vikram Singh, Narendra Modi, Modi, Reema Bhattacharya, Verisk, Modi's, he's, Samir Kapadia, Nirmala Sitharaman, Santanu Sengupta, Goldman Sachs, Sengupta, Richard Rossow, Kapadia, Sumedha Gupta, Vivek Prasad, Prasad, Mark Mobius, David Roche Organizations: Bharatiya Janata Party, BJP, Infrastructure, India Index, Vogel Group, Nurphoto, CNBC, Center for Strategic, International Studies, Padget Electronics, Dixon Technologies, Bloomberg, Getty, Research, India Electronics, Semiconductor Association, Economist Intelligence Unit, Centre, Monitoring, National Stock Exchange of, World Federation of Exchanges Locations: India, Asia, China, Mumbai, Noida, PwC India, National Stock Exchange of India

☆ Veteran investor David Roche 'optimistic' U.S. rate cuts are coming
▼ + stars: | 2024-06-17 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailVeteran investor David Roche 'optimistic' U.S. rate cuts are comingDavid Roche, president and global strategist at Independent Strategy, weighs in on the outlook for U.S. interest rates, saying he is "optimistic" that cuts are coming.

Persons: David Roche Organizations: Independent

☆ Roche alleges counterfeit diabetes medical devices were sold on Amazon
▼ + stars: | 2024-06-10 | by ( Scott Zamost | ) www.cnbc.com time to read: +4 min

Roche Diabetes Care Inc. Accu-Chek brand glucose test strips are arranged for a photograph in the Brooklyn borough of New York, U.S., on Thursday, April 4, 2019. Roche , one of the world's largest biotech companies, said "dangerous counterfeits" of its diabetes medical devices ended up for sale on Amazon to be bought by patients throughout the United States. "Patients know that Roche's Accu-Chek medical devices are safe, sterile and accurate," the complaint said. After the suit was filed, a judge granted Roche's request for a temporary restraining order to stop the defendants from selling the counterfeit products. The complaint was filed on behalf of Roche Diabetes Care Inc., Roche Diabetes Care GmbH and Hoffmann-La Roche Inc, by attorneys with the New York-based law firm Patterson Belknap Webb & Tyler.

Persons: Roche, Patterson Belknap Webb, Tyler, Dileep Kumar Yadav, Abhishek Jain, Ratnakar Sharma, Atikur Rahman Organizations: Roche Diabetes Care Inc, Amazon, CNBC, Roche Diabetes Care GmbH, Hoffmann, Roche Inc, New, JMD Enterprises, JMD, JMD International Locations: Brooklyn, New York, U.S, United States, India, New York City

☆ Roche alleges counterfeit diabetes devices sold on Amazon
▼ + stars: | 2024-06-10 | by ( Kate Rooney | ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailRoche alleges counterfeit diabetes devices sold on AmazonCNBC's Kate Rooney joins 'Power Lunch' to discuss the lawsuit filed by Roche for fake medical devices being sold on Amazon.

Persons: Email Roche, Kate Rooney, Roche Organizations: Amazon

☆ Modi's weaker-than-expected election win raises questions over his economic and political agenda
▼ + stars: | 2024-06-05 | by ( Sumathi Bala | ) www.cnbc.com time to read: +5 min

Indian Prime Minister Narendra Modi gestures as he arrives at Bharatiya Janata Party (BJP) headquarters in New Delhi, India, June 4, 2024. he said, adding Modi will likely have an "uneasy relationship" with its coalition partners. Veteran investor David Roche called the election outcome an exercise of "karma," adding that this was Modi's election to lose. The party suffered some of its high-profile losses here, with political BJP heavyweights like Smriti Irani among others, losing their seats. A 'humbling moment'Going into the election, Modi's popularity endured despite India's economic problems such as high youth unemployment, inflation and income inequality.

Persons: Narendra Modi, Adnan Abidi, Modi, Neelanjan Sircar, We've, Sircar, CNBC's, —, David Roche, Roche, Smriti Irani, overreach, he's, Michael Kugelman, Wilson Organizations: Indian, Bharatiya Janata Party, BJP, Centre for Policy Research, Indian National Congress, Developmental Inclusive Alliance, Independent, South Asia Institute Locations: New Delhi, India, INDIA, Uttar Pradesh, Ayodhya, Faizabad, Maharashtra, Rajasthan

☆ Roche's head of cardiovascular disease dissects GLP-1 drug trial results
▼ + stars: | 2024-06-05 | by ( ) www.cnbc.com time to read: 1 min

In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailRoche's head of cardiovascular disease dissects GLP-1 drug trial resultsManu Chakravarthy, Roche SVP & global head of cardiovascular disease, joins 'Fast Money' to talk the company's recent weight-loss drug trial results.

Persons: Manu Chakravarthy Organizations: Roche SVP

☆ How This 300-Year-Old Pastel Stick Maker Creates Nearly 2,000 Colors
▼ + stars: | 2024-06-03 | by ( Sarah Elkasaby | Claudia Romeo | ) www.businessinsider.com time to read: 1 min

Henri Roché pastels are highly coveted for their particular texture, ability to adhere to most mediums, and intensity of colors. For over 300 years, La Maison du Pastel has handcrafted these pastels, used by artists like Degas. Today, the company is run and operated by just two women — Isabelle Roché, a distant relative of Henri Roché, and Margaret Zayer. But it's taken them decades of work since Isabelle took over the dying company in 2000 to build it back up to where it is today. We visited their secret workshop in the French countryside to see how La Maison du Pastel is still standing.

Persons: Henri, Degas, — Isabelle Roché, Henri Roché, Margaret Zayer, it's, Isabelle Organizations: Business

☆ Analog Devices CEO Vincent Roche on Q2 earnings
▼ + stars: | 2024-05-22 | by ( ) www.cnbc.com time to read: 1 min

In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailAnalog Devices CEO Vincent Roche on Q2 earningsAnalog Devices CEO Vincent Roche joins CNBC's 'Money Movers' to discuss the company's earnings report, implementing AI, and more.

Persons: Vincent Roche, CNBC's

☆ The ultimate anti-aging skincare routine you should try before getting Botox, according to 2 dermatologists
▼ + stars: | 2024-05-18 | by ( Julia Pugachevsky | ) www.businessinsider.com time to read: +7 min

"The best anti-aging routine can be as simple as just a few steps," especially in the morning, Lindsey Zubritsky, a board-certified dermatologist, told Business Insider. Always cleanse your face — unless you have sensitive skin"I recommend starting out with a gentle cleanser if you have oily or acne-prone skin," Zubritsky said. AdvertisementZubtritsky recommended Cetaphil Gentle Cleanser, a creamier formula for dry or sensitive skin. For oilier skin, she suggested La Roche Posay Toleriane Foaming Cleanser, which can also be used for sensitive skin. AdvertisementIf you have sensitive skin, you'll want to start with retinol, Zubritsky said, as it's gentler.

Persons: —, Lindsey Zubritsky, Carolyn Stull, Sergey Mironov, Zubritsky, that's, Stull, Cetaphil, La Roche, ISDIN Eryfotona, Skinbetter, Blair Murphy, Rose, Olay, you've Organizations: Service, Business, Neutrogena Hydro, L'Oreal, Cream

☆ Eli Lilly falls on a rival's obesity study — plus, we're removing 3 stocks from our watchlist
▼ + stars: | 2024-05-16 | by ( Jeff Marks | ) www.cnbc.com time to read: +5 min

Eli Lilly dips: Shares of Eli Lilly are sitting out the rally on news that Swiss pharmaceutical firm Roche 's experimental obesity drug demonstrated promise in a Phase 1 study. "Doug McMillon, the CEO of Walmart, made the point repeatedly that the company's success this quarter came from lower prices," Jim Cramer said. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB.

Persons: Jim Cramer, Eli Lilly, Roche, It's, inflect, We're, Doug McMillon, Estee Lauder, Jim, Jim Cramer's Organizations: CNBC, Viking Therapeutics, Club, Deere, Walgreens Boots, Walmart, Costco, Materials, Jim Cramer's Charitable Locations: Swiss, Amgen, China

☆ Roche says weight loss drug shows promising results in early trial
▼ + stars: | 2024-05-16 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +2 min

Roche on Thursday said its experimental weight loss drug showed promising results in an early-stage trial, boosting the company's bid to compete in the booming market for those treatments. But its weekly weight loss injection, called CT-388, is still years away from entering the market. The treatment works by mimicking the effect of two gut hormones — GLP-1 and GIP — to suppress a person's appetite, just like Eli Lilly's popular weight loss drug Zepbound and diabetes injection Mounjaro. Scientists have hypothesized that targeting those two hormones could have a meaningful effect on weight loss and blood sugar levels with fewer side effects than drugs that only target GLP-1, such as Novo Nordisk's weight loss treatment Wegovy. Eli Lilly's Zepbound delivered up to 22% weight loss after 72 weeks, while Novo Nordisk's Wegovy has led to 15% weight loss after 68 weeks.

Persons: Roche, Eli Lilly, Roche's, —, Eli Lilly's, Eli Lilly's Zepbound, Novo Nordisk's Wegovy Organizations: Roche, AG, Carmot Therapeutics, Novo Nordisk, Novo Nordisk's Locations: Basel, Switzerland, Swiss, Roche's, Novo

☆ FDA greenlights self-collection of vaginal samples for cervical cancer screening
▼ + stars: | 2024-05-15 | by ( Jacqueline Howard | ) edition.cnn.com time to read: +6 min

Most cervical cancers are caused by human papillomavirus or HPV, and screening for HPV can help identify women who may be at risk of developing cervical cancer. The US Preventive Services Task Force recommends screening for cervical cancer with cervical cytology every three years for women ages 21 to 29. “Most cervical cancers are found in people who have never had a cervical cancer screening test or who have not had one recently. Screening for cervical cancer remains important because early cases often may not have signs or symptoms. Cervical cancer is treated in many ways, including surgery, chemotherapy and radiation therapy.

Persons: Dickson, BD –, Dr, Karen E, Knudsen, “, Jeff Andrews, ”, Roche, ” Dr, William Dahut, Sanjay Gupta, ” Trena Depel Organizations: CNN, US Food and Drug Administration, Roche, Company, BD, FDA, American Cancer Society, US Preventive Services Task Force, National Cancer Institute, US Centers for Disease Control, ”, CNN Health, Health, Teal Health Locations: United States

☆ Bank of Japan has 'put a floor under the yen,' but it is not on 'firm footing,' David Roche says
▼ + stars: | 2024-05-13 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailBank of Japan has 'put a floor under the yen,' but it is not on 'firm footing,' David Roche saysDavid Roche, president and global strategist at Independent Strategy, discusses the Bank of Japan's monetary policy and the Japanese yen.

Persons: David Roche Organizations: Email Bank of Japan, Independent, Bank

☆ David Roche: The Japanese aren't aiming for a particularly strong yen
▼ + stars: | 2024-05-09 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailDavid Roche: The Japanese aren't aiming for a particularly strong yenDavid Roche, president and global strategist at Independent Strategy, says they're aiming for a "relatively stable" yen.

Persons: David Roche Organizations: Independent

☆ Japan not seeking a strong yen but a stable currency, David Roche says
▼ + stars: | 2024-05-09 | by ( Sumathi Bala | ) www.cnbc.com time to read: +2 min

Japan is not seeking a strong yen but rather aiming for a relatively stable currency, according to veteran investor David Roche. The Japanese yen has been on a roller coaster ride, with the currency breaking past 160 against the greenback last week — steepest decline in more than three decades. "The Japanese are not aiming at a particularly strong yen. Japan could not "possibly speak to have policy that really results in a strong yen unless they tighten monetary policy," Roche said, adding that it would involve raising interest rates by at least 50 basis points and allowing "unsterilized intervention" of the yen. As far as I can see from the statistics, they've [Bank of Japan] done nothing like that," Roche noted.

Persons: David Roche, Roche, CNBC's Organizations: greenback, Independent, Bank of Japan, Bank of Locations: Japan, Bank of Japan

☆ GNC is redesigning stores to draw people taking Ozempic
▼ + stars: | 2024-04-29 | by ( Nathaniel Meyersohn | ) edition.cnn.com time to read: +3 min

The brand hopes a new strategy tailored to people taking GLP-1 drugs for weight loss will help draw customers into stores and grow its business. We can help,” advertises an overhead banner in GNC’s new GLP-1 “support section.”GNC's new GLP-1 support section is available in all 2,300 stores across the United States. JON SIMON/GNCDanish pharmaceutical company Novo Nordisk is reaping huge profits from creating and selling the hit GLP-1 products. JPMorgan researchers estimate that 30 million people may be taking GLP-1 drugs by 2030, or around 9% of the US population. GNC, which filed for bankruptcy in 2020 and closed more than 1,200 stores, is the latest brand to build a strategy around people taking GLP-1s.

Persons: New York CNN — GNC, GNC, ”, JON SIMON, WeightWatchers Organizations: New, New York CNN, Novo Nordisk, Pfizer, Roche, JPMorgan, Equinox Locations: New York, United States, Danish

One strategist, however is looking keenly at European equities, and notes that "Europe isn't a boring market." "You would hope that will translate through to the stock market in terms of company earnings growth in Europe. "While you might see some kind of short-term downturn, in the longer-term the picture is very positive for the sector," Field added. He sees value in payments, which he described as "one of the most undervalued parts of European financial services." The sector has trailed market performance, with valuations looking "interesting" over the last 12 months, Morningstar noted in its recent report.

Persons: Michael Field, Field, Morningstar Organizations: CNBC Pro, European Central Bank, Consumer, Swatch Group, Financial, Morningstar, ING Bank, Group, Health, Novo Nordisk Locations: U.S, Europe, Netherlands, British, Swiss

☆ Google is once again dictating the future of the online ad industry and all its rivals can do is brace for impact
▼ + stars: | 2024-04-24 | by ( Lara O'Reilly | ) www.businessinsider.com time to read: +7 min

When Google sneezes, the entire online advertising industry catches a cold. Google's announcement Tuesday that it would again delay its planned timeline for killing off third-party tracking cookies had long been anticipated by the digital advertising industry. Google has a 28% share of the online ad market, according to market research firm Emarketer (a sister company to BI). Regulators could step in to resolve the cookie chaosSome industry experts are hoping regulators will step in to untangle the mess. Amid the four years of confusion, chaos, and harumphing, there has been one consistent theme: When it comes to the future of online advertising, Google calls the shots.

Persons: Ciaran O'Kane, WireCorp, hasn't, Sundar Pichai, Stephen Lam, Mathieu Roche, James Rosewell, Google's, haven't, Pierre Devoize, Devoize Organizations: Google, Business, Gmail, Antitrust, US Department of Justice, European Commission, UK's, Markets Authority, CMA, Industry, IAB Tech, EU Google, Chrome, Movement Locations: FirstPartyCapital

☆ Swiss pharma giant Roche's first-quarter sales edge higher as its emerges from post-Covid-19 slump
▼ + stars: | 2024-04-24 | by ( Karen Gilchrist | ) www.cnbc.com time to read: +1 min

Swiss pharmaceutical company Roche on Wednesday reported a modest uptick in first-quarter sales, even as waning demand for its Covid-19 products continued to weigh on the company. Sales were up 2% at constant exchange rates, led by stronger demand for Roche's newer medicines and diagnostics, the company said. Excluding Covid-19 products, sales were up 7%. But sales tightened when reported in the company's local currency, down 6% off the back of a strong Swiss franc. Roche CEO Thomas Schinecker on Wednesday confirmed the company's 2024 outlook, saying it was largely out of the woods following a post-Covid-19 slump.

Persons: Roche, Thomas Schinecker, Schinecker Organizations: Roche, AG, Wednesday, Reuters Locations: Basel, Switzerland, Swiss

☆ Israel vows to 'exact a price' after Iran's attack. Here's what analysts expect could happen
▼ + stars: | 2024-04-15 | by ( Lee Ying Shan | In Ying-Shan-Lee | ) www.cnbc.com time to read: +4 min

But Israel will need to strike a delicate balance, he noted, highlighting that "they don't want an overt conflict with Iran." Iran has said the attack on Israel was in response to an Israeli strike on its embassy compound in Damascus, Syria earlier this month. The Islamic regime has accused Israel of the April 1 attack which killed seven Iranian military personnel, including senior commanders. Israel and Iran have been at odds for decades, with Iran funding and supporting groups opposing Israel including Palestinian militant group Hamas. The ongoing conflict in Gaza has often been referred to as a proxy war between Israel and Iran.

Persons: Amir Cohen, Israel, Joe Biden, Ryan Bohl, Bohl, CNBC's, Biden, Benjamin Netanyahu, Benny Gantz, Amir Saeid Iravani, Bashar al, Assad, David Roche, Roche, Israel's, What's Organizations: Reuters, Middle East, Rane, NBC News, United Nations, Palestinian, Hamas, Yemeni, Independent, CNBC Locations: Gaza, Ashkelon, Israel, Reuters Israel, Iran, North Africa, Damascus, Syria, Tehran, United States

☆ David Roche: Israeli escalation against Iran is 'baked in the cake'
▼ + stars: | 2024-04-15 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailDavid Roche: Israeli escalation against Iran is 'baked in the cake'David Roche, president and global strategist at Independent Strategy, discusses Iran's drone and missile attack on Israel and says "you have all degrees of escalation that are possible, but escalation you will get — there's no doubt about that."

Persons: David Roche Organizations: Independent Locations: Iran, Israel

☆ Check out the pitch deck that helped adtech identity company ID5 raise $20 million from investors including TransUnion and Martin Sorrell's S4S
▼ + stars: | 2024-04-09 | by ( Lara O'Reilly | ) www.businessinsider.com time to read: +4 min

Adtech company ID5 said Tuesday it had raised $20 million in Series B investment. The ID5 identifier has been deployed by more than 66,000 publishers, per the metadata company Sincera. ID5 has now raised just over $27 million in funding to date, though the company declined to disclose its post-money valuation. New investors in this round included the credit reporting and data agency TransUnion and advertising veteran Martin Sorrell's venture capital firm S4S Ventures. Check out key slides from the pitch deck that helped ID5 raise $20 million in Series B funding.

Persons: ID5, Mathieu Roche, Martin Sorrell's, Sorrell, Matt Spiegel, Spiegel, Matt, Roche Organizations: Business, Data Protection, Publishers, Trade, S4S Ventures, Progress Ventures, Seventure Partners, Capital Partners, Aperiam Ventures

☆ Robert Kiyosaki, David Einhorn, and Gary Shilling are all worried about inflation — and so is the Fed
▼ + stars: | 2024-04-04 | by ( Theron Mohamed | ) www.businessinsider.com time to read: +4 min

The central bank's current chief, Jerome Powell, is yet to defeat his mythical beast — and Wall Street is getting worried. Powell warned on Wednesday that the Fed's fight against inflation isn't over after annualized price growth accelerated to 3.2% in February. AdvertisementRaising the alarmBank of America analysts have suggested that stubborn inflation could mean the Fed doesn't start cutting rates until March next year. It's no wonder, then, that investors are waiting impatiently for the Fed to cut rates. Fundstrat's famously bullish boss, Tom Lee, proclaimed this week that it's dropping "like a rock" and the first rate cut is still likely to be in June.

Persons: —, Paul Volcker, Jerome Powell, Powell, Greenlight Capital's David Einhorn, Einhorn, Greenlight, Dad, Robert Kiyosaki, Gary Shilling, Julia La Roche, We've, Merrill Lynch's, they've, Shilling, It's, Fundstrat's, Tom Lee Organizations: Service, Federal, Business, of America, CNBC, Trust, Wall Street, Fed

☆ The bottom of interest rate in the new cycle will be much higher: David Roche and Euan Munro
▼ + stars: | 2024-03-25 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailThe bottom of interest rate in the new cycle will be much higher: David Roche and Euan MunroEuan Munro of Newton Investment and David Roche of Independent Strategy discuss the possibility of the Federal Reserve reducing interest rates against the backdrop of high government spending and budget deficits in the United States.

Persons: David Roche, Euan Munro Euan Munro Organizations: Newton Investment, Independent, Federal Reserve Locations: United States

☆ Nvidia's AI ambitions in medicine and health care are becoming clear
▼ + stars: | 2024-03-24 | by ( Michelle Castillo | ) www.cnbc.com time to read: +3 min

Last week, Nvidia announced deals with Johnson & Johnson for use of generative AI in surgery, and with GE Healthcare to improve medical imaging. "Health care, whether it's biotechnology, chemicals, or drug discovery is a very powerful area." About 41 percent of biotech CEOs surveyed by EY in late 2023 said they were looking at "concrete" ways generative AI could be used for their companies. "This is very high for my experience, having been 30 years in this industry," Ural said. It also partnered in 2021 with Schrödinger for drug discovery.

Persons: Johnson, Raj Joshi, It's, EY, it's, Colette Kress, Roche's Genentech Organizations: Nvidia, Johnson, GE Healthcare, Companies, NVIDIA, NVIDIA BioNeMo Locations: Arda, Americas, Ural, NVIDIA Clara

Search resuls for: "Roche"

25 mentions found